Vivimed Labs Approves Unaudited Financial Results, EGM Notice, and Application to NCLT
Vivimed Labs approves unaudited financial results for Q2 FY26, plans EGM for NCLT application, and expects trading suspension revocation. The company did not provide for interest expenses of ₹157.28 million for the quarter.
The approval to file for insolvency resolution process and qualified audit opinions indicate financial challenges, but the expectation of trading suspension revocation provides some positive offset.
The announcement includes both positive developments (expected revocation of trading suspension) and negative aspects (approval of NCLT application due to financial stress and qualified opinions from auditors).
* Approved unaudited standalone & consolidated financial results for the quarter and half year ended September 30, 2025. * Approved filing of an application to National Company Law Tribunal (NCLT) under pre-packaged insolvency resolution process, subject to shareholder approval via Special Resolution. * Approved the draft EGM Notice for seeking the consent of Members by way of EGM through remote e-voting for making an application under Section 54A and other applicable provisions read with Section 10 of IBC to Hon'ble National Company Law Tribunal, Bengaluru Bench. * Expects Revocation of Suspension in trading in equity shares of the Company from stock exchanges in few days. * The company has not provided for interest expenses of ₹157.28 million on an accrual basis for the Quarter ended 30.09.2025, (₹307.11 million for the year to date 30.09.2025) pertaining to loans.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.